Form 4: Humana Executive David Dintenfass Reports Stock Transactions
SEC Form 4 Filing
David Dintenfass, President of Enterprise Growth at Humana Inc., reports acquisition and disposal of Humana common stock and stock options.
Summary
- On February 21, 2025, David Dintenfass disposed of 1,175 shares of Humana common stock at a price of $258.575 per share to cover tax liabilities related to vested restricted stock units.
- On February 24, 2025, Dintenfass acquired 4,360 shares of Humana common stock at $0.
- Following these transactions, Dintenfass directly owns 16,234 shares of Humana common stock.
- Dintenfass also holds options to buy 51,389 shares of Humana common stock at a price of $367.21, which were granted on February 21, 2024, and vest in three annual increments from February 21, 2025, to February 21, 2027.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Positives
- The acquisition of 4,360 shares could be interpreted as a positive sign of confidence in Humana's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the healthcare industry, similar to how investors track filings from executives at UnitedHealth Group, CVS Health, and Anthem (now Elevance Health).
- The vesting schedule of the stock options (three annual increments) is a standard practice for executive compensation packages.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are part of standard executive compensation and tax management practices.
- Shareholders may be interested in the transactions as an indicator of executive sentiment, but the impact is likely to be small.
Key Dates
| Date | Description |
|---|---|
| 02/21/2024 | Incentive and Non-Qualified stock options granted to reporting person. |
| 02/21/2025 | Date of earliest transaction; disposal of shares for tax liability; first vesting date of stock options. |
| 02/21/2027 | Final vesting date of stock options. |
| 02/24/2025 | Acquisition of Humana common stock. |
| 02/25/2025 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.